Table 1 Patients’ characteristics in the first cohort of 129 CN-AML patients according to MAP7 expression levels.
Variable | MAP7high, n = 64 | MAP7low, n = 65 | P |
|---|---|---|---|
Median age, y (range) | 47.5 (18–59) | 45 (16–59) | 0.55 |
FAB subtype, no (%) | |||
M0 | 2 (3.1) | 0 (0.0) | 0.24 |
M1 | 21 (32.8) | 20 (30.8) | 0.85 |
M2 | 15 (23.4) | 7 (10.8) | 0.06 |
M4 | 8 (12.5) | 13 (20.0) | 0.34 |
M5 | 14 (21.9) | 21 (32.3) | 0.24 |
M6 | 1 (1.6) | 0 (0.0) | 0.5 |
Other | 3 (4.7) | 4 (6.2) | 1 |
FLT3-ITD, no (%) | 37 (57.8) | 21 (32.3) | 0.005 |
FLT3-TKD, no (%) | 9 (14.0) | 9 (13.8) | 1 |
NPM1Mut/FLT3WT, no (%) | 9 (14.0) | 10 (15.4) | 1 |
CEBPA, mutated, no (%) | |||
Single | 3 (4.7) | 1 (1.5) | 0.37 |
Double | 2 (3.1) | 13 (20.0) | 0.005 |
IDH1 mutated, no (%) | 8 (12.5) | 10 (15.4) | 0.8 |
IDH2 mutated, no (%) | 8 (12.5) | 4 (6.15) | 0.24 |
High ERG, no (%) | 42 (65.6) | 22 (33.8) | 0.0004 |
High BAALC, no (%) | 34 (53.1) | 30 (46.2) | 0.48 |
High LEF1, no (%) | 27 (42.1) | 37 (57.0) | 0.11 |
High WT1, no (%) | 50 (78.1) | 14 (21.5) | <0.0001 |
High DNMT3B, no (%) | 45 (70.3) | 19 (29.2) | <0.0001 |
High DNMT3A, no (%) | 38 (59.4) | 26 (40.0) | 0.03 |
High MAPKBP1, no (%) | 39 (61.0) | 25 (38.5) | 0.01 |
High ITPR2, no (%) | 40 (62.5) | 24 (36.9) | 0.005 |
High ATP1B1, no (%) | 43 (67.2) | 21 (32.3) | <0.001 |
